3 News & Press Releases found

ITM Isotope Technologies Munich SE news

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administratio

Oct. 27, 2022

ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177

An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), announced today the commencement of commercial production of lutetium-177.

The announcement was celebrated at ITM’s headquarters in Munich, Germany, along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade.

This miles

Oct. 24, 2022

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted

Oct. 19, 2022